New biologic FB102 takes on celiac disease in Mid-Stage trial
NCT ID NCT06982963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new biologic drug called FB102 in 100 adults with celiac disease who already follow a strict gluten-free diet. Participants will receive either FB102 or a placebo and then undergo a controlled gluten challenge to see if the drug can reduce intestinal damage and symptoms. The goal is to find a better way to manage accidental gluten exposure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FB102 (a biologic drug given by infusion or injection)
What this could lead to
If it works, this could point toward a new treatment to help people with celiac disease better manage their condition even when accidentally exposed to gluten.
What could go wrong
This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. The drug may not show benefit or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Royal Melbourne Hospital
RECRUITINGMelbourne, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••